COLESTIPOL HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COLESTIPOL HYDROCHLORIDE (COLESTIPOL HYDROCHLORIDE).
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.
| Metabolism | Not metabolized; not absorbed systemically. |
| Excretion | Colestipol hydrochloride is not absorbed systemically; it is excreted entirely in the feces as the intact polymer, without undergoing metabolism. No renal or biliary elimination occurs. |
| Half-life | Not applicable as colestipol is not absorbed; it acts locally in the gastrointestinal tract and has no systemic half-life. |
| Protein binding | Not applicable; the drug is not absorbed and does not bind to plasma proteins. |
| Volume of Distribution | Not applicable; colestipol is not absorbed and remains within the gastrointestinal lumen. |
| Bioavailability | 0% for systemic absorption; it is non-absorbable and acts locally in the intestine. |
| Onset of Action | 1-2 weeks for reduction in serum total and LDL cholesterol levels after oral administration. |
| Duration of Action | Duration persists for 24 hours with daily dosing; maximal effect may require 1 month of therapy. |
| Molecular Weight | 5400 Da (average, as hydrochloride salt) |
Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment recommended; use with caution in severe renal impairment due to potential for hyperchloremic metabolic acidosis. |
| Liver impairment | No specific dose adjustment recommended; caution in severe hepatic impairment due to possible decreased cholesterol synthesis. |
| Pediatric use | Not established for children <10 years; for ≥10 years, initial: 5 g orally once daily; increase gradually to 5-20 g/day divided once or twice daily. |
| Geriatric use | No specific dose adjustment; monitor for gastrointestinal adverse effects and potential interactions with other medications due to altered GI motility and polypharmacy. |
| 1st trimester | Colestipol hydrochloride is not systemically absorbed and is considered low risk; however, caution is advised as fat-soluble vitamin absorption may be impaired. |
| 2nd trimester | No known teratogenic effects; use only if clearly needed due to potential for vitamin deficiency. |
| 3rd trimester | May impair absorption of fat-soluble vitamins; consider monitoring and supplementation if used near term. |
Clinical note
Comprehensive clinical and safety monograph for COLESTIPOL HYDROCHLORIDE (COLESTIPOL HYDROCHLORIDE).
| Placental transfer | Not expected to cross placenta due to high molecular weight and poor systemic absorption; no significant placental transfer documented. |
| Breastfeeding | Colestipol is not systemically absorbed and is unlikely to pass into breast milk; however, theoretical risk of impaired maternal absorption of fat-soluble vitamins that could affect milk composition. Use with caution. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to colestipol or any componentComplete biliary obstruction
| Precautions | May cause hypertriglyceridemia, Risk of vitamin K deficiency and bleeding (due to bile acid binding), May impair absorption of fat-soluble vitamins (A, D, E, K), May cause constipation or fecal impaction (especially in elderly), May interfere with absorption of other drugs (e.g., warfarin, thyroid hormones, digoxin); separate administration by at least 1 hour or as specified |
| Food/Dietary | Colestipol can bind to dietary fats and fat-soluble vitamins (A, D, E, K). Take supplements at least 1 hour before or 4-6 hours after colestipol. High-fiber foods may reduce binding but are generally encouraged to prevent constipation. Avoid grapefruit juice? No significant interaction. |
Loading safety data…
| Lactation Rating | L3: Moderately Safe |
| Teratogenic Risk | Colestipol hydrochloride is not absorbed systemically, thus no direct fetal exposure. No teratogenic risk expected. First trimester: minimal risk. Second/third trimester: no known adverse fetal effects. |
| Fetal Monitoring | Monitor maternal lipid profiles, coagulation parameters (prothrombin time) due to potential vitamin K deficiency, and maternal nutritional status. Assess fetal growth if prolonged use. |
| Fertility Effects | No known effects on fertility. Theoretical interference with fat-soluble vitamin absorption does not impact fertility. |
| Clinical Pearls | Colestipol hydrochloride is a bile acid sequestrant used as adjunctive therapy for primary hyperlipidemia. It may increase triglyceride levels; monitor triglycerides before initiation. Administer other medications 1 hour before or 4-6 hours after colestipol to reduce absorption interference. Use with caution in constipation-prone patients; encourage high-fiber diet and adequate fluid intake. Can bind thyroxine, warfarin, digoxin, and fat-soluble vitamins. |
| Patient Advice | Take colestipol with meals and plenty of water (at least 8 oz). · Do not take other medications within 1 hour before or 4-6 hours after colestipol. · May cause constipation; increase dietary fiber and fluid intake. · Report severe constipation, abdominal pain, or unusual bleeding. · Continue prescribed diet and exercise regimen. · Store at room temperature; do not freeze. |